XML 72 R34.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaborative, Licensing and Other Arrangements (Details) | 12 Months Ended | 36 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended |  | 12 Months Ended | 1 Months Ended | 12 Months Ended |  |  | 3 Months Ended |  | 1 Months Ended | 12 Months Ended |  |  |  | 1 Months Ended | 12 Months Ended |  |  | 1 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2013 USD ($) Milestone | Dec. 31, 2012 USD ($) | Dec. 31, 2011 USD ($) | Dec. 31, 2013 Milestone | Dec. 31, 2013 License Arrangement [Member] License | Dec. 31, 2013 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 1 [Member] USD ($) | Dec. 31, 2012 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 1 [Member] USD ($) | Dec. 31, 2011 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 1 [Member] USD ($) | Oct. 31, 2011 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 1 [Member] USD ($) | Dec. 31, 2013 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2012 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2011 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2010 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2009 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Sep. 30, 2008 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 2 [Member] USD ($) | Dec. 31, 2012 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 3 [Member] USD ($) | Jul. 31, 2006 National Institute of Allergy and Infectious Diseases "NIAID" [Member] Arrangement with Governmental Agency 3 [Member] USD ($) | Dec. 31, 2007 Pfizer Inc. [Member] License Arrangement [Member] USD ($) | Jan. 31, 2011 Collaborative Arrangement [Member] Servier [Member] USD ($) | Jan. 31, 2011 Collaborative Arrangement [Member] Servier [Member] EUR (€) | Dec. 31, 2013 Collaborative Arrangement [Member] Servier [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Servier [Member] USD ($) | Dec. 31, 2011 Collaborative Arrangement [Member] Servier [Member] USD ($) | Dec. 31, 2013 Collaborative Arrangement [Member] Servier [Member] Sales And Development Milestones [Member] USD ($) | Dec. 31, 2010 Collaborative Arrangement [Member] Servier [Member] Up-front Payment Arrangement [Member] USD ($) | Sep. 30, 2010 Collaborative Arrangement [Member] Servier - U.S. Perindopril Franchise [Member] USD ($) | Dec. 31, 2013 Collaborative Arrangement [Member] Servier - U.S. Perindopril Franchise [Member] Product | Feb. 28, 2009 Collaborative Arrangement [Member] Takeda [Member] | Nov. 30, 2006 Collaborative Arrangement [Member] Takeda [Member] | Dec. 31, 2013 Collaborative Arrangement [Member] Takeda [Member] USD ($) | Dec. 31, 2012 Collaborative Arrangement [Member] Takeda [Member] USD ($) | Dec. 31, 2011 Collaborative Arrangement [Member] Takeda [Member] USD ($) | Dec. 31, 2013 Collaborative Arrangement [Member] Takeda [Member] Development Milestone [Member] USD ($) | Feb. 28, 2009 Collaborative Arrangement [Member] Takeda [Member] Sales Milestone [Member] USD ($) | Nov. 30, 2006 Collaborative Arrangement [Member] Takeda [Member] Sales Milestone [Member] USD ($) | Nov. 30, 2008 Collaborative Arrangement [Member] Novartis [Member] USD ($) | Dec. 31, 2013 Collaborative Arrangement [Member] Novartis [Member] USD ($) | Nov. 30, 2008 Collaborative Arrangement [Member] Novartis [Member] Development Milestone [Member] USD ($) Product | Dec. 31, 2013 Collaborative Arrangement [Member] Pfizer Inc. [Member] Sales Milestone [Member] USD ($) | Jan. 31, 2014 Non-arrangement Transactions [Member] Pfizer Inc. [Member] Development Milestone [Member] USD ($) | Dec. 31, 2011 Non-arrangement Transactions [Member] Pfizer Inc. [Member] Development Milestone [Member] USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period for recognizing deferred revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from loan |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,500,000 | 15,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total contract amount awarded |  |  |  |  |  |  |  |  | 28,000,000 | 3,000,000 |  |  |  |  | 64,800,000 |  | 16,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contractual term |  |  |  |  |  | 5 years |  |  |  | 3 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 900,000 |  | 1,100,000 |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Recognition of deferred revenue |  |  |  |  |  | 4,700,000 | 2,500,000 | 100,000 |  | 4,400,000 | 6,600,000 | 18,600,000 | 21,200,000 |  |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 | 1,200,000 | 2,000,000 |  |  |  |  |  |  |  |  |
Future initial research and development expenses to be funded by counterparty |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future other expenses to be funded by counterparty (in hundredths) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Licensing and collaboration agreement revenue | 11,028,000 | 5,727,000 | 17,991,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,600,000 | 14,500,000 | 34,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payments, maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 488,000,000 |  |  |  |  |  |  |  |  |  | 3,250,000 | 19,000,000 |  |  | 14,000,000 |  |  |
Future milestone payments, repurchase option not exercised, maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 827,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of fixed-dose combination product candidates included in a portfolio of antihypertensive products from Servier |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |
License fees paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Future milestone payments with each additional future qualifying product candidate development, maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 20,750,000 |  |  |  |  |  |  |  | 1,700,000
Royalty right expiration period |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10 years | 13 years 6 months |  |  |  |  |  |  | 20 years |  |  |  |  |
Proceeds from collaborators |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,200,000 |  |  |  |  |
Reduction in debt under restructured agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,500,000 |  |  |  |  |
Number of ongoing product programs with potential royalty right milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |
Maximum borrowing capacity under agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50,000,000 |  |  |  |
Research and development expenses funded through loan facility, maximum (in hundredths) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 75.00% |  |  |  |
Additional future milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,200,000 |  |
Number of licenses granted, minimum |  |  |  |  | 60 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from license fees received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of undisclosed product candidates with milestone payments received | 12 |  |  | 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of milestone received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 25.00% |
Milestone received under the collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,000,000 |
Repayment of debt |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,750,000 |
Euro to US Dollar exchange rates | 1.3766 | 1.3766 |  | 1.3766 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Amount billed to customers under long-term contracts or programs but not paid. Excludes amounts due that have been withheld because of retainage provisions in a contract. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 910 -SubTopic 310 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6471494&loc=d3e49354-109356 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3(c)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph c -Article 5 + Details
Name: | us-gaap_AccountsReceivableBilledForLongTermContractsOrPrograms
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Decrease for amounts of indebtedness forgiven by the holder of the debt instrument. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(f)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 08 -Paragraph f -Article 4 + Details
Name: | us-gaap_DebtInstrumentDecreaseForgiveness
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The net addition or reduction in the carrying amount of deferred revenue during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).(Q1)) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenuePeriodIncreaseDecrease
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521 + Details
Name: | us-gaap_ForeignCurrencyExchangeRateTranslation1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndServicesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate carrying amount, as of the balance sheet date, of liabilities not separately disclosed in the balance sheet. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Article 9 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_OtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + References No definition available. + Details
Name: | us-gaap_ProceedsFromIssuanceOfDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. For cash flows, this element primarily pertains to amortization of deferred credits on long-term arrangements. As a noncash item, it is deducted from net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A -Subsection 1 + Details
Name: | us-gaap_RecognitionOfDeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of additional potential cash payments that the Company could receive from collaborative arrangements. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationAdditionalPotentialCashPayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Refers to the maximum future development and sales milestone payments to be received by the Company. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentMaximum
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of potential cash payments that the Company will receive should the Company not reacquire intangible assets produced as a result of collaborative agreements. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentRightsNotReacquired
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of potential cash payments that the Company could receive from collaborative arrangements for each of the additional future qualifying product candidate developed. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementContingentConsiderationPotentialCashPaymentWithEachAdditionalFutureQualifyingProductCandidateDevelopment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum percentage of aggregate costs of clinical research and development expenses that are funded through a debt instrument under collaborative arrangements and are not incurred by the Company. + References No definition available. + Details
Name: | xoma_CollaborativeArrangementResearchAndDevelopmentExpenseFundedThroughDebtInstrumentPercentageMaximum
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contractual term of collaborative, licensing and other arrangements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | xoma_ContractualTerm
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum borrowing capacity for a debt instrument under the loan agreement. + References No definition available. + Details
Name: | xoma_DebtInstrumentMaximumBorrowingCapacity
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The period over which deferred or unearned revenue is recognized as revenue during the period. + References No definition available. + Details
Name: | xoma_DeferredRevenueRevenueRecognitionPeriod
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate amount of future initial clinical research and development expenses that will be funded by the counterparty under a collaborative arrangements. + References No definition available. + Details
Name: | xoma_FutureInitialResearchAndDevelopmentExpensesToBeFundedByCounterpartyUnderCollaborativeArrangement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount paid to a licensor for license fee during the period. + References No definition available. + Details
Name: | xoma_LicenseFeeAmountPaid
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Refers to the timing of required repayments to its customers. + References No definition available. + Details
Name: | xoma_LongTermDebtMaturitiesRepayment
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Refers to the payment percentage of milestone received under the collaboration agreement. + References No definition available. + Details
Name: | xoma_MilestoneReceivedUnderCollaborationAgreement
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of fixed-dose combination ("FDC") product candidates included in a portfolio of antihypertensive products from Servier. + References No definition available. + Details
Name: | xoma_NumberOfFixedDoseCombinationProductCandidatesIncludedInPortfolioOfAntihypertensiveProductsFromServier
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Maximum number of licenses granted by the Company. + References No definition available. + Details
Name: | xoma_NumberOfLicensesGrantedMinimum
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of ongoing product programs with potential royalty right milestone payments. + References No definition available. + Details
Name: | xoma_NumberOfOngoingProductProgramsWithPotentialRoyaltyRightMilestonePayments
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of undisclosed product candidates relating to which milestone payments received during the period. + References No definition available. + Details
Name: | xoma_NumberOfUndisclosedProductCandidatesWithMilestonePaymentsReceived
Namespace Prefix: | xoma_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of aggregate costs of other expenses not specifically stated that are funded through collaborative arrangements and are not incurred by the Company. + References No definition available. + Details
Name: | xoma_OtherExpenseFundedThroughCollaborativeArrangementPercentage
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Refers to percentage of milestone received. + References No definition available. + Details
Name: | xoma_PercentageOfMilestoneReceived
Namespace Prefix: | xoma_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash received from upfront payment under a license and collaboration agreement during the current period. + References No definition available. + Details
Name: | xoma_ProceedsFromUpfrontPaymentReceived
Namespace Prefix: | xoma_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Refers to royalty right expiration period. + References No definition available. + Details
Name: | xoma_RoyaltyRightExpirationPeriod
Namespace Prefix: | xoma_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration